Try our beta test site

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

This study has been completed.
Sponsor:
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)
National Institutes of Health (NIH)
Information provided by (Responsible Party):
CONRAD
ClinicalTrials.gov Identifier:
NCT01687218
First received: August 27, 2012
Last updated: December 7, 2016
Last verified: December 2016

August 27, 2012
December 7, 2016
June 2013
May 2015   (Final data collection date for primary outcome measure)
  • Safety: Grade 2 or Higher Adverse Events [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    Compare the safety profiles of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Analysis of the primary endpoint of grade 2 or higher AEs was performed on only the evaluable participants based on the principle of intent-to-treat (ITT) whereby participants who were randomized were included in the analysis regardless of whether or not they received product in a given period (i.e, were lost to follow-up, or terminated early and/or were on a product hold).
  • Acceptability: Participant Self-report of Liking the Product. H1-Overall How do You Feel About the Product You Used Recently? [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of liking the product, a variable was created by combining from Section H. Liking the Product of the MTN-017 Follow-up Behavioral Questionnaire question 1A and question 1BC. Categories 1 and 2 were combined and categories 3 and 4 were combined to create a dichotomous variable.
  • Acceptability: Participant Self-report of Ease of Use. I1-Overall How Easy or Difficult Was it to Use the Product? [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of ease of use, a variable was created to compare regimens. This variable combines questions 1A and 1BC from Section I. Ease of Use of the MTN-017 Follow-up Behavioral Questionnaire. Categories 1 and 2 were combined and categories 3 and 4 were combined to create dichotomous variables.
  • Acceptability: Participant Self-report of Likelihood of Product Use if Shown to be Effective. N1-If This Product Provides Some Protection How Likely Would You be to Take it? [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel. Consistent with the acceptability endpoint of likelihood to use product in the future, a variable was created by combining Section N. Likelihood to Use Product in the Future of the MTN-017 Follow-up Behavioral Questionnaire questions 1A, 1B, and 1C. Categories 1 and 2 were combined and categories 3 and 4 were combined to create a dichotomous variable.
  • Saftey Profiling
    Compare the safety profiles of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel
  • Acceptability
    To evaluate and compare acceptability of daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel
Complete list of historical versions of study NCT01687218 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To compare systemic and local PK among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel
  • Adherence [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To evaluate and compare adherence to daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel
  • Pharmacokinetics
    To compare systemic and local PK among daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel
  • Adherence
    To evaluate and compare adherence to daily FTC/TDF tablet, daily TFV RG 1% gel, and RAI-associated TFV RG 1% gel
  • Pharmacodynamics [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To characterize pharmacodynamic responses following oral and rectal exposure to antiretroviral drugs
  • Mucosal Immunity [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To characterize changes in mucosal immunity between baseline and the end of the daily FTC/TDF and TFV RG 1% gel product use
  • Correlation Between PK and Adherence [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To assess correlation of PK with adherence measures
  • Factors Associated With Adherence [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To identify factors associated with product adherence and whether they differ by product used (FTC/TDF or TFV RG 1% gel) or regimen (daily use or RAI-associated use)
  • Sexual Activity and Condom Use [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To examine whether sexual activity or condom use varies by product used
  • Product Sharing [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To determine the level of sharing of study products with non-participants and to assess with whom products are shared
  • Problem Practices [ Time Frame: 27 weeks (three 8-week product use periods with 1-week washout periods between them) ]
    To determine the prevalence of behavioral practices associated with anal intercourse that may affect microbicide use
  • Pharmacodynamics
    To characterize pharmacodynamic responses following oral and rectal exposure to antiretroviral drugs
  • Mucosal Immunity
    To characterize changes in mucosal immunity between baseline and the end of the daily FTC/TDF and TFV RG 1% gel product use
  • Correlation Between PK and Adherence
    To assess correlation of PK with adherence measures
  • Factors Associated With Adherence
    To identify factors associated with product adherence and whether they differ by product used (FTC/TDF or TFV RG 1% gel) or regimen (daily use or RAI-associated use)
  • Sexual Activity and Condom Use
    To examine whether sexual activity or condom use varies by product used
  • Product Sharing
    To determine the level of sharing of study products with non-participants and to assess with whom products are shared
  • Problem Practices
    To determine the prevalence of behavioral practices associated with anal intercourse that may affect microbicide use
 
Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel
MTN-017 is a Phase 2, multi-site, randomized, six-sequence, two three-period, open label crossover study, examining the effects of oral Truvada and reduced glycerin 1% tenofovir gel. The study population will be sexually active, HIV-uninfected males who are 18 years of age or older, who report a history of receptive anal intercourse in the past 3 months. Each of the study product regimens offers different advantages to participants seeking an effective HIV prevention agent. How these relative advantages will compare in terms of safety, acceptability, systemic and local absorption, and adherence will be examined within this study.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
HIV
  • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
  • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Active Comparator: Group 1
    Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
    Interventions:
    • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
    • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
    • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Active Comparator: Group 2
    Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
    Interventions:
    • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
    • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
    • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Active Comparator: Group 3
    Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
    Interventions:
    • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
    • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
    • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Active Comparator: Group 4
    Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
    Interventions:
    • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
    • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
    • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Active Comparator: Group 5
    Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks); followed by Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks)
    Interventions:
    • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
    • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
    • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
  • Active Comparator: Group 6
    Receptive Anal Intercourse Associated Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks);followed by Daily Rectally-Applied Tenofovir Reduced Glycerin 1% Gel (8 weeks); followed by Daily Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet (8 weeks)
    Interventions:
    • Drug: Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)
    • Drug: Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)
    • Drug: Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
195
May 2015
May 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Male or transgender female > age of 18 at Screening
  2. Able and willing to provide written informed consent
  3. HIV-1 uninfected at Screening and Enrollment
  4. Able and willing to provide adequate locator information, as defined in site SOP
  5. Available to return for all study visits, barring unforeseen circumstances and willing to comply with study participation requirements
  6. In general good health at Screening and Enrollment, as determined by the site IoR or designee
  7. Per participant report, a history of consensual RAI at least once in the past 3 months
  8. Per participant report at Screening and Enrollment, agrees not to engage in receptive or insertive sexual activity with another study participant for the duration of study participation.
  9. Willing to use study-provided condoms for the duration of the study for penetrative intercourse
  10. Willing to not take part in other research studies involving drugs, medical devices, vaccines or genital products for the duration of study participation (including the time between Screening and Enrollment)
  11. Men and transgender females who agree to take part in the PK, PD and Mucosal Immunology Subset, must also agree to abstain from:

    • Inserting anything into the rectum, including abstaining from RAI for 72 hours after the collection of biopsies
    • Taking non-steroidal anti-inflammatory drugs (NSAIDs), aspirin and/or other drugs that are associated with increased likelihood of bleeding following mucosal biopsy collection for 72 hours prior to and following the collection of biopsies.

Exclusion Criteria:

  1. At Screening, participant-reported symptoms, and/or clinical or laboratory diagnosis of active anorectal or reproductive tract infection requiring treatment per current World Health Organization (WHO) guidelines or symptomatic urinary tract infection (UTI). Infections requiring treatment include symptomatic Chlamydia trachomatis (CT) infection, Neisseria gonorrhea (GC), syphilis, active herpes simplex virus (HSV) lesions, anogenital sores or ulcers, or symptomatic genital warts.

    Note: HSV-1 or HSV-2 seropositive diagnosis with no active lesions is allowed, since treatment is not required.

    In cases of non-anorectal GC/CT identified at screening, one re-screening 2 months after the screening visit will be allowed

  2. History of inflammatory bowel disease as reported by participant history
  3. At Screening:

    • Positive for hepatitis B surface antigen
    • Positive for hepatitis C antibody
    • Hemoglobin < 10.0 g/dL
    • Platelet count less than 100,000/mm3
    • White blood cell count < 2,000 cells/mm3 or > 15,000 cells/mm3
    • Calculated creatinine clearance less than 60 mL/min by the Cockcroft-Gault formula where creatinine clearance in mL/min = (140 - age in years) x (weight in kg) x (1 for male)/72 x (serum creatinine in mg/dL)
    • Serum creatinine > 1.3 x the site laboratory upper limit of normal (ULN)
    • Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) > 2.5× the site laboratory ULN
    • PK, PD and Immunological Subset only: International normalized ratio (INR) > 1.5× the site laboratory ULN or partial thromboplastin time (PTT) > 1.25× the site laboratory ULN
  4. Known allergy to methylparaben and/or propylparaben
  5. Known allergy to any of the study products.
  6. Per participant report, use of the following medications and/or products within 12 weeks prior to screening, and/or anticipated use or unwillingness to abstain from use throughout study participation:

    • Any investigational products
    • Systemic immunomodulatory medications
    • Use of Heparin, including Lovenox®
    • Warfarin
    • Plavix® (clopidogrel bisulfate)
    • Rectally-administered medications or products, containing N-9 or corticosteroids
  7. By participant report, use of post-exposure prophylaxis (PEP) for HIV exposure within the 12 weeks prior to screening or anticipated use during study participation.
  8. Symptoms suggestive of acute HIV seroconversion at Screening and Enrollment
  9. Has any other condition that, in the opinion of the IoR/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable/unwilling to comply with the study requirements. Such conditions may include, but are not limited to, colorectal abnormalities, substance abuse, or renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological or psychiatric disease.
Sexes Eligible for Study: Male
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States,   Peru,   Puerto Rico,   South Africa,   Thailand
 
 
NCT01687218
MTN-017
5UM1AI068633 ( US NIH Grant/Contract Award Number )
11857 ( Other Identifier: DAIDS protocol # )
Yes
Not Provided
Not Provided
Not Provided
CONRAD
CONRAD
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of Mental Health (NIMH)
  • National Institutes of Health (NIH)
Study Chair: Ross D. Cranston, MD, FRCP University of Pittsburgh Medical Center (UPMC)
Study Chair: Javier R. Lama, MD, MPH Asociacion Civil Impacta Salud y Educacion (IMPACTA)
CONRAD
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP